Table 3. Clinical characteristics of 140... | American Society of Hematology

Table 3.

Clinical characteristics of 140 elderly patients with acute myeloid leukemia by mutation status

	RAS					FLT3					TP53
	Mutant (N = 26)		Wild-type (N = 114)		P^3-150	Mutant (N = 47)		Wild-type (N = 93)		P^3-150	Mutant (N = 12)		Wild-type (N = 128)		P^3-150
Cytogenetics^3-151	No.	%	No.	%		No.	%	No.	%		No.	%	No.	%
Favorable	2	9	7	8	.96	3	10	6	8	.0008	0	0	9	9	< .0001
Intermediate	15	68	58	67		28	90	45	58		1	9	72	73
Unfavorable	5	23	22	25		0	0	27	35		10	91	17	17

	RAS					FLT3					TP53
	Mutant (N = 26)		Wild-type (N = 114)		P^3-150	Mutant (N = 47)		Wild-type (N = 93)		P^3-150	Mutant (N = 12)		Wild-type (N = 128)		P^3-150
Cytogenetics^3-151	No.	%	No.	%		No.	%	No.	%		No.	%	No.	%
Favorable	2	9	7	8	.96	3	10	6	8	.0008	0	0	9	9	< .0001
Intermediate	15	68	58	67		28	90	45	58		1	9	72	73
Unfavorable	5	23	22	25		0	0	27	35		10	91	17	17

	Med	Range	Med	Range		Med	Range	Med	Range		Med	Range	Med	Range
Age	68	56-77	67	56-88	.86	64	56-80	68	56-88	.032	71	62-88	66	56-84	.036
Marrow blasts (%)	61	4-97	71	0-99	.032	76	19-97	70	0-99	.0026	62	5-94	70	0-99	.37
WBC (10³/μL)	31.9	1.5-274	28.2	0.7-298	.49	59.4	1.2-298	20.3	0.7-274	.0003	23.7	1.6-81.7	29.0	0.7-298	.25
Peripheral blasts (%)	8	0-93	43	0-99	.004	68	0-99	27	0-95	.0001	36	0-93	35	0-99	.67
Peripheral blasts (10³/μL)	4.2	0-119	10.1	0-292	.11	26.6	0-292	4.1	0-119	.0001	10.2	0-52.2	8.7	0-292	.48
CD34⁺ blasts (%)	42	0-90	48	0-95	.56	13	0-95	65	0-95	.0039	50	0-93	46	0-95	.96

	Med	Range	Med	Range		Med	Range	Med	Range		Med	Range	Med	Range
Age	68	56-77	67	56-88	.86	64	56-80	68	56-88	.032	71	62-88	66	56-84	.036
Marrow blasts (%)	61	4-97	71	0-99	.032	76	19-97	70	0-99	.0026	62	5-94	70	0-99	.37
WBC (10³/μL)	31.9	1.5-274	28.2	0.7-298	.49	59.4	1.2-298	20.3	0.7-274	.0003	23.7	1.6-81.7	29.0	0.7-298	.25
Peripheral blasts (%)	8	0-93	43	0-99	.004	68	0-99	27	0-95	.0001	36	0-93	35	0-99	.67
Peripheral blasts (10³/μL)	4.2	0-119	10.1	0-292	.11	26.6	0-292	4.1	0-119	.0001	10.2	0-52.2	8.7	0-292	.48
CD34⁺ blasts (%)	42	0-90	48	0-95	.56	13	0-95	65	0-95	.0039	50	0-93	46	0-95	.96

	Est	95% CI	Est	95% CI		Est	95% CI	Est	95% CI		Est	95% CI	Est	95% CI
CR (%)	42	23-62	46	36-55	.83	55	40-70	40	30-50	.11	17	2-48	48	39-57	.065
RD (%)	35	17-56	31	22-40	.82	19	9-33	38	28-48	.034	33	10-65	31	23-40	1.0
Median OS (mo)	8	3-12	7	4-9	.35	8	6-12	7	3-8	.45	1	1-4	8	6-9	.0007
Median RFS (mo)	7	3-10	8	6-10	.33	8	4-10	8	6-10	.97	—^3-152	—	8	6-10	.0002

	Est	95% CI	Est	95% CI		Est	95% CI	Est	95% CI		Est	95% CI	Est	95% CI
CR (%)	42	23-62	46	36-55	.83	55	40-70	40	30-50	.11	17	2-48	48	39-57	.065
RD (%)	35	17-56	31	22-40	.82	19	9-33	38	28-48	.034	33	10-65	31	23-40	1.0
Median OS (mo)	8	3-12	7	4-9	.35	8	6-12	7	3-8	.45	1	1-4	8	6-9	.0007
Median RFS (mo)	7	3-10	8	6-10	.33	8	4-10	8	6-10	.97	—^3-152	—	8	6-10	.0002

RD indicates resistant disease; for other abbreviations, see Table 2.

F3-150

Two-tailed P value comparing mutant to wild-type groups for each gene (based on Fisher exact test for cytogenetic abnormality, CR, and RD; Wilcoxon rank sum test for continuous variables; Pearson's χ² test for cytogenetic pattern; and log-rank test for OS and RFS).

F3-151

Thirty-one patients with nonevaluable cytogenetics excluded.

F3-152

Only 2 patients positive for p53 achieved CR, which ended in relapses after 24 and 56 days.

View Large

This Feature Is Available To Subscribers Only